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Initial results: Doses measured by TLD were
on average by 4% lower than doses pre-
calculated using the modified algorithm. Mean
doses normalized to those pre-calculated and
their standard deviations (both in per cents)
were respectively: 96.1 % and 0.4 % for
phantom with diameter of 20; 96.5% and
0.7% for diameter of 30 cm and 96.0% and
0.8% for diameter of 40 cm.
Conclusions: Measured doses proved
correctness of elaborated algorithm. Very low
standard deviations are resulting from regular
cylindrical shape of the phantoms.
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Introduction: RT plays an important role in
the management of LABC, yet clinical outcomes
still remain far from satisfactory. The aim of this
study was to evaluate retrospectively factors
determining local control in a large series of
consecutive LABC pts managed with RT as the
primary locoregional treatmenł.
Material and methods: The records of 261
primarily inoperable LABC pts treated between
1991 and 1997 at two institutions: Medical
University of Gdansk, Poland and Velindre NHS
Trust, Cardiff, UK were analysed. Ali pts
received megavoltage RT to the breast with two
tangential fields, and the adjacent Iymph node
areas were irradiated using customised fields.
Due to a large scale of RT doses and
fractionation schedules, normalised total dose
(NTD) was calculated for all patients using a
linear quadratic model. In 241 pts RT constituted
the only local treatment and the remaining 20
pts were subsequently subjected to
mastectomy. Most pts received chemotherapy
and/or endocrine therapy prior or after RT.
Results: Within the median follow-up of 37
months, locoregional recurrence occurred in 95
of 251 evaluable pts (38%). Three-year and five-
year locoregional-free survival rates were 59%
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and 48%, respectively. At multivariate analysis
of variabies predicting the risk of locoregional
relapse, inflammatory carcinoma (p<0.01; RR
2.1), T4 disease (p<0.01; RR 2.9) and
involvement of supraclavicular Iymph nodes
(p<0.01; RR 2.4) were the most significant
clinical factors, whereas response to RT
(p<0.01; RR 1.2) and NTD (p<0.01; RR 0.7)
were the most important therapeutic factors.
Increasing the total dose to the tumour by 10 Gy
was associated with 30% reduction of local
relapse.
Conclusions: Due to large heterogeneity of
LABC pts, judicious tailoring of RT, particularly
in terms of dose prescribing, is essential to
increase the chance of locoregional cure.
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Aim: to discuss some problems of the
"conventionality" in the prospective and
retrospective studies finished last year at the RT
Department in Warsaw. The phase III c1inical
trial. The study was conducted according to the
evidence based rules. Cancer of the larynx -
glottis and supraglottis T1 - T3 NO MO WHO O-
1, 395 cases 196 in experimental, 199 in
conventional arm. The retrospective study
concerned all patients with the cancer of larynx
treated radically in the II department in years
1989 to May 1995. 372 patients T1- T4, N1-N3,
MO. The prospective material 150 patients were
selected [age 75 and less, WHO 0-1, T1-T3, NO,
MO] employing the same selection criteria as in
the prospective study. The comparison was
performed with the conventional arm of the
clinical trial [199 cases].
Results of the study: Significant differences
were recorded in the: ? performance status and
in the number of T1 and T3 cases, ? compliance
to protocol in the total dose and the overall
treatment time, ? response to treatment in the
whole group and in the particular stages These
results indicate the very demanding selection of
cases and much more rigorous compliance with
the therapeutic protocol in the prospective study.
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The response to treatment was about 20%
higher in the clinical trial group. The 20%
difference between the outcomes in the
prospective and retrospective studies recorded
in the response to treatment was similar in the 1,
2, and 3 years local controi observations.
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Intensity Modulated Radiotherapy (IMRT) is
going to revolutionise treatment planning and
delivery of radiotherapy in the next few years.
Although there are still technological constraints,
IMRT allows delivery of a specified dose-
distribution that is superior to what is realistically
achievable with 3D conformal radiotherapy
using standard techniques. This forces a re-
think of the whole process of delivering
radiotherapy. With our current technology, the
physics has overtaken the biology and it
appears that to realise the fuli potential of IMRT,
a major research effort on the biological aspects
of radiotherapy is needed. This goes far beyond
traditional cellular radiobiology. New powerful
assays in molecular biology and bioimaging will
be key elements in the biological optimisation of
radiotherapy. In this lecture, I will try to identify
some of the research areas that will need to be
further developed in order to get the fuli
therapeutic benefit from IMRT.
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STEREOTACTIC RADIOTHERAPY
FOR PRIMARY AND RECURRENT
BRAIN TUMORS. A NEW METHOD
FOR IMPROVEMENT OF THE
TREATMENT RESUlTS?
J. Fijuth
Centrum Onkologii - Instytut, Warszawa
To evaluate the effectiveness of the
stereotactic radiosurgery (SRS) and stereotactic
fractionated radiotherapy in the primary,
recurrent and metastatic brain tumors.
To present potential usefulness of stereotactic
boost in anaplastic astrocytomas (AA) and
glioblastoma multiforme (GBM).
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Between March 2000 and December 2000,
SRS was applied in 23 patients (pts) with brain
tumors (metastatic tumors - 9 pts, recurrent
tumors - 7 pts, primary meningiomas - 4 pts,
vascular malformations - 3 pts).
Fractionated stereotactic radiotherapy was
applied in 6 pts (recurrent anaplastic gliomas - 2
pts, recurrent medulloblastoma - 1 pt, acustic
neurinoma - 1 pt, meningioma - 1, pituitary
adenoma - 1).
Detailed technique of treatment planning is
presented and discussed. The planning target
volume (PTV) and organs at risk (OAR) were
assessed comparing dose statistics, dose
volume histograms and RTOG stereotactic
radiosurgery criteria.
Recommendations regarding the total dose
level and fractional dose are proposed.
The treatment tolerance and preliminary results
are presented.
The own protocol of stereotactic boost to
residual tumor using SRS after initial conformal
radiotherapy in patients with AA and GBM is
presented and discussed.
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Monte Carlo (MC) particie transport
simulations are increasingly applied in treatment
planning methods. This has become feasible
through a number of adaptations of general MC
codes, such as EGS4 ar ETRAN, to the specific
needs of treatment planning. The currently most
advanced "conventional" planning methods,
such as convolution or delta-volume algorithms
still have serious limitations in terms of accuracy
when tissue inhomogeneities, smali and
complex body shapes or high-density implants
are involved. The Monte Carlo simulation
mimics individual particie transport, in any
applicable geometry, by applying first principles
of radiation interaction with matter and random
choice of collision parameters such as step
length, type of interaction, energies and
scattering angles. In principle, the accuracy of
MC calculations is only Iimited the radiation
beam quality definition and the interaction
parameters and can be taken to below 12%. In
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